Summary
Led design of internal tool for 23andMe & Lemonaid medical teams, enabling personalized care via automation; established new design system for Internal Tools.
Led design of internal tool for 23andMe & Lemonaid medical teams, enabling personalized care via automation; established new design system for Internal Tools.
3 years (FY2022 Q2 - FY2025 Q1)
Product Design Owner
Product was not classified as medical device, limiting design solutions.
New design solutions could not significantly alter existing medical processes, to reduce mental load.
Product was expected to support 1400% more patients than with Lemonaid’s EMR.
Shifting priorities led to this project requiring polished deliveries vs. an iterative approach.
Between team re-orgs and business strategy pivots, Clinical Portal—our in-house EMR— faced numerous challenges over its 3-year lifetime.
The creation of a new EMR gave us many opportunities to re-invent existing medical processes, resulting in numerous efficiency increases for our entire medical team.
Automating clinician tasks led to over an 80% increase in efficiency across numerous workflows.
With fewer manual tasks, our providers were able to spend more time personalizing patient care.
Created a new design system for Internal Tools, optimizing design and ENG efficiency by over 100%.
After meeting our medical team’s needs, our users migrated and we sun-set the legacy EMR platform.
Product Design Lead
Dmitry Stupakov — Product Manager Lead 1
Nicole Fox — Product Manager Lead 2
Mary-Padgett Hawkins — Product Manager
Jeffrey Kalmikoff — Principal Designer
Matthew Walvick — Head of Medical
Dawna Blocher — Director of Medical Operations
Davis Liu, m.d. — Head of Service Development
Danny Au — Team Lead
Jason Tan — Team Lead
Basel Qumsiyeh — Principal Engineer
Jimmy Chau — Front-end Engineer
Michael Kim — Front-end Engineer
... and many, many more
After acquiring Lemonaid Health Inc. in 2021, 23andMe began redefining its product strategy, pivoting into personalized healthcare. By prioritizing disease prevention, 23andMe aimed to help patients understand their genetic predispositions and deliver tailored guidance to reduce and even eliminate health risks.
Design started in FY2022 Q2.
Employee Pilot launched in FY2022 Q4.
Design iterations from FY2023 Q1 - FY2023 Q3.
v1.0 launched on FY2023 Q4 alongside 23andMe. +Total Health.
Design iterations and feature launches every FQ from FY2024 Q1 - FY2025 Q1.
This project's case study includes detailed, client-sensitive work. Request access to view my full design process.
If you've already recieved access, use your unique link to continue.
Request Access